Second meeting of the WHO Strategic and Technical Advisory Group working group on access to safe, efficacious and quality-assured health products for neglected tropical diseases


Book Description

The STAG Working Group on access to safe, efficacious and quality-assured health products for neglected tropical diseases was established in 2021 to facilitate alignment of stakeholders on strategies and best practices for improving access to medicines and other health products for NTDs. The Working Group held its second technical meeting virtually on 19 September 2023. The main outcomes of the meeting were to expand the scope of drug efficacy monitoring to include other neglected tropical diseases and to seek synergy in addressing common issues and challenges across diseases for procurement and supply chain management. In addition to the Working Group’s members, observers, invited guests and the WHO secretariat attended the meeting. This publication contains the report of the meeting and its recommendations to STAG, which will be helpful as a reference and of use to the wider NTD community.




Investing to Overcome the Global Impact of Neglected Tropical Diseases


Book Description

"The presence, or absence, of neglected tropical diseases (NTDs) can be seen as a proxy for poverty and for the success of interventions aimed at reducing poverty. Today, coverage of the public-health interventions recommended by the World Health Organization (WHO) against NTDs may be interpreted as a proxy for universal health coverage and shared prosperity - in short, a proxy for coverage against neglect. As the world's focus shifts from development to sustainable development, from poverty eradication to shared prosperity, and from disease-specific goals to universal health coverage, control of NTDs will assume an important role towards the target of achieving universal health coverage, including individual financial risk protection. Success in overcoming NTDs is a "litmus test" for universal health coverage against NTDs in endemic countries. The first WHO report on NTDs (2010) set the scene by presenting the evidence for how these interventions had produced results. The second report (2013) assessed the progress made in deploying them and detailed the obstacles to their implementation. This third report analyses for the first time the investments needed to achieve the scale up of implementation required to achieve the targets of the WHO Roadmap on NTDs and universal coverage against NTDs. INVESTING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES presents an investment strategy for NTDs and analyses the specific investment case for prevention, control, elimination and eradication of 12 of the 17 NTDs. Such an analysis is justified following the adoption by the Sixty-sixth World Health Assembly in 2013 of resolution WHA6612 on neglected tropical diseases, which called for sufficient and predictable funding to achieve the Roadmap's targets and sustain control efforts. The report cautions, however, that it is wise investment and not investment alone that will yield success. The report registers progress and challenges and signals those that lie ahead. Climate change is expected to increase the spread of several vector-borne NTDs, notably dengue, transmission of which is directly influenced by temperature, rainfall, relative humidity and climate variability primarily through their effects on the vector. Investments in vector-borne diseases will avoid the potentially catastrophic expenditures associated with their control. The presence of NTDs will thereby signal an early warning system for climate-sensitive diseases. The ultimate goal is to deliver enhanced and equitable interventions to the most marginalized populations in the context of a changing public-health and investment landscape to ensure that all peoples affected by NTDs have an opportunity to lead healthier and wealthier lives."--Publisher's description.




Working to Overcome the Global Impact of Neglected Tropical Diseases


Book Description

"Neglected tropical diseases (NTDs) blight the lives of a billion people worldwide and threaten the health of millions more. These ancient companions of poverty weaken impoverished populations, frustrate the achievement of health in the Millennium Development Goals and impede global health and economies has convinced governments, donors, the pharmaceutical industry and other agencies, including nongovernmental organizations (NGOs), to invest in preventing and controlling this diverse group of diseases. Global efforts to control "hidden" diseases, such as dracunculiasis (guinea-worm disease), leprosy, gains including the imminent eradication of dracunculiasis. Since 1989 (when most endemic countries began reporting monthly from each endemic village), the number of new dracunculiasis cases has fallen from 892 055 in 12 endemic countries to 3190 in 4 countries in 2009, a decrease of more than 99%. The World Health Organization (WHO) recommends five public-health strategies for the prevention and control of NTDs: preventive chemotherapy; intensified case-management; vector control; the provision of safe water, sanitation and hygiene; and veterinary public health (that is, applying veterinary sciences to ensure the health and well-being of humans). Although one approach and delivered locally." - p. vii







First WHO Model List of Essential In Vitro Diagnostics


Book Description

The objective of the list is to help countries develop or update their national essential diagnostics lists, raise awareness and political will, guide procurement and regulation policies and improve access to the most important in vitro diagnostics that all countries need to make available to their populations, particularly in low-resourced countries. It will also contribute towards health systems strengthening and realizing universal health coverage.




Global Technical Strategy for Malaria 2016-2030


Book Description

The World Health Organization's Global Technical Strategy for Malaria 2016- 2030 has been developed with the aim to help countries to reduce the human suffering caused by the world's deadliest mosquito-borne disease. Adopted by the World Health Assembly in May 2015 it provides comprehensive technical guidance to countries and development partners for the next 15 years emphasizing the importance of scaling up malaria responses and moving towards elimination. It also highlights the urgent need to increase investments across all interventions - including preventive measures diagnostic testing treatment and disease surveillance- as well as in harnessing innovation and expanding research. By adopting this strategy WHO Member States have endorsed the bold vision of a world free of malaria and set the ambitious new target of reducing the global malaria burden by 90% by 2030. They also agreed to strengthen health systems address emerging multi-drug and insecticide resistance and intensify national cross-border and regional efforts to scale up malaria responses to protect everyone at risk.




WHO guideline on country pharmaceutical pricing policies


Book Description

In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.




Bench Aids for the Diagnosis of Intestinal Parasites


Book Description

A set of nine A-4 color plates with 118 photomicrographs illustrating the appearance and diagnostic features of all the common intestinal helminths and protozoan parasites known to infect humans. Produced in a robust plasticized format, the plates can be used as either a guide for laboratory and field workers in endemic countries, or a teaching aid for students and trainees. The aim is to help the microscopist ascertain the presence of parasites in feces, whether they be minute protozoan cysts or large helminth eggs, and to identify them correctly. With this goal in mind, the bench aids include pertinent laboratory instructions as well as high-quality images. The photomicrographs illustrate diagnostic features of each of the parasites as they appear in different preparations and at different magnifications. Each photomicrograph is produced with a measuring bar and accompanied by a short explanatory legend, which draws attention to distinctive features that help confirm diagnosis. Helminth eggs are illustrated in the first 36 photomicrographs, which show the diagnostic stages of the most common helminthes, including nematodes, cestodes, schistosomes, and other trematodes. The remaining photomicrographs offer advice on the more difficult task of detecting and identifying intestinal protozoan trophozoites and cysts. Relevant laboratory techniques are described on the reverse side of the plates. Additional laboratory aids include dichotomous keys for the identification of amoebic trophozoites trophozoites of intestinal flagellates, and cysts of amoebae and flagellates.




Rare Diseases and Orphan Products


Book Description

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.